Kringle Pharma (TSE:4884) Other Stockholders Equity: 円34.46 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4884 Kringle Pharma Inc TSE:4884
40 GF Score
Price 円323.00
GF Value 円490.24
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Kringle Pharma Other Stockholders Equity?

Kringle Pharma TSE:4884 -5.00% 40 Other Stockholders Equity is 円34.46 Mil as of Mar. 2026. GuruFocus rates TSE:4884 with a GF Score™ of 40/100 and a GF Value™ of 円490.24 (Possible Value Trap). The stock has 5 warning signs investors should review.

Kringle Pharma's Other Stockholders Equity for the quarter that ended in Mar. 2026 was 円34.46 Mil.

Kringle Pharma's quarterly Other Stockholders Equity increased from Sep. 2025 (円29.85 Mil) to Dec. 2025 (円32.14 Mil) and increased from Dec. 2025 (円32.14 Mil) to Mar. 2026 (円34.46 Mil).

Kringle Pharma's annual Other Stockholders Equity increased from Sep. 2023 (円14.70 Mil) to Sep. 2024 (円18.25 Mil) and increased from Sep. 2024 (円18.25 Mil) to Sep. 2025 (円29.85 Mil).

Kringle Pharma Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Kringle Pharma's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kringle Pharma Other Stockholders Equity Chart

Kringle Pharma Annual Data
Trend Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Other Stockholders Equity
Get a 7-Day Free Trial 0.00 3.37 14.70 18.25 29.85

Kringle Pharma Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.54 26.37 29.85 32.14 34.46
TSE:4884
40GF Score
Kringle Pharma Inc TSE:4884
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kringle Pharma Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of 円34.46 Mil mean?
Kringle Pharma (TSE:4884) has a Other Stockholders Equity of 円34.46 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Kringle Pharma and its competitors.
Is Kringle Pharma's Other Stockholders Equity too high?
Kringle Pharma's current Other Stockholders Equity is 円34.46 Mil. Overall, Kringle Pharma has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Kringle Pharma's Other Stockholders Equity compare to VRTX and REGN?
Kringle Pharma's Other Stockholders Equity of 円34.46 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Kringle Pharma and its competitors. Kringle Pharma's current Other Stockholders Equity is 円34.46 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kringle Pharma stock overvalued right now?
Based on GuruFocus' analysis, Kringle Pharma (TSE:4884) is currently considered Possible Value Trap. The stock's GF Value™ is 円490.24, compared to a current price of 円323.00 — trading 34.1% below its estimated fair value. The current Other Stockholders Equity is 円34.46 Mil. Kringle Pharma's overall GF Score™ is 40/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Kringle Pharma (TSE:4884), the current Other Stockholders Equity is 円34.46 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kringle Pharma (TSE:4884) Overvalued in 2026?

Based on GuruFocus' analysis, Kringle Pharma stock appears to be undervalued. The current stock price of 円323.00 is trading 34.1% below its estimated GF Value™ of 円490.24. GuruFocus considers Kringle Pharma to be Possible Value Trap.

Key valuation signals for TSE:4884:

  • Other Stockholders Equity: 円34.46 Mil
  • GF Value™: 円490.24 vs. price of 円323.00 (34.1% below fair value)
  • GF Score™: 40/100 with 5 warning signs

No single metric tells the full story. See the TSE:4884 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kringle Pharma Business Description

Address 7-7-15 Saito asagi, 207 Saito Bio-Incubator, Osaka Prefecture, Ibaraki, JPN, 567-0085
Kringle Pharma Inc is engaged in the research and development of HGF (hepatocyte growth factor) protein as a therapeutic agent for intractable diseases. The Company operates in a single segment, pharmaceutical development.
40GF Score

Get the complete analysis for TSE:4884

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円323.00
Price
円490.24
GF Value